Campanelli, a company specializing in commercial real estate development, acquisition, and construction management, in collaboration with the private equity firm TriGate Capital, has recently announced a significant development. A 15-year, full-building lease agreement with renewal options has been signed with Moderna Therapeutics at Upland in Norwood.
Moderna intends to establish an mRNA clinical manufacturing facility within the 200,000-square-foot building situated at 100 Tech Drive. The leasing process was facilitated by the Newmark Grubb Knight Frank team, comprising leasing agents Mike Frisoli, Taryn Wilson, and Matt Morgan. JLL Managing Directors Peter Bekarian and Tom Kent, along with Executive Vice President Don Domoretsky, represented Moderna during the negotiation.
The Norwood facility by Moderna is designed to support the advancement of the company’s mRNA pipeline, spanning from development candidate nomination to human proof-of-concept. This site will play a crucial role in the manufacturing, quality control, and supply of clinical-grade mRNA therapies and vaccines. It will cater to good laboratory practices in toxicology studies, as well as phase 1 and phase 2 clinical studies. The initial construction of the facility is scheduled to commence in October 2016, with plans for its official opening in early 2018.